Former Professor of Internal Medicine, Nightingale Medical
College & Jahurul Islam Medical College, Dhaka University. • tremor, • a weak and clumsy limb, • a stiff and aching limb, and • a gait disorder There is no ideal way to define PD and distinguish it from other parkinsonian syndromes. Nevertheless, PD needs to be differentiated from mimics 3 Diagnostic error rate in a community sample was 47%. 4 So suspected patients should be referred, early & untreated, to a specialist with sufficient expertise in movement disorders 16 . It is difficult even for experts to differentiate essential tremor from PD when asymmetric postural and action tremor of the upper limbs appears at rest. In this situation, 123 I-FP-CIT SPECT should be considered. 5 Intravenous isotope tagged to a cocaine derivative binds to the presynaptic dopamine reuptake site in the striatum, which is visualized using a gamma camera. Uptake is reduced in those with PD, PD dementias, and Parkinsonian syndromes. 2 Routine use of functional imaging is not recommended for the differential diagnosis of Parkinson's disease and Parkinson's plus disorders such as progressive supranuclear palsy and multiple system atrophy. 16 Objective olfactory testing is not recommended in the diagnosis of Parkinson's disease. 16 
Functional Neuroanatomy & Basal Ganglia Circuitry:
Motor function is not just locomotion but also the subtle automatic motor activities & adjustments that give us a smooth flow in speech, swallowing, communicating body language, vision, writing, playing musical instruments…. Basal ganglia and cerebellum modulate the activity of motor cortex and the descending motor pathways. The basal ganglia are subcortical nuclei: 
Subthalamic nucleus[STN]
The action of basal ganglia is inhibitory. The output nuclei of the basal ganglia discharge tonically at high frequency to inhibit their target nuclei in the thalamus. Major inputs to the neostriatum are:
1. Glutamatergic input from sensory, motor, and association cortex 1. Excitation of the direct pathway ultimately disinhibits the thalamic neurons i.e. exciting thalamic neurons (which in turn make excitatory connections onto cortical neurons). Activation of the direct pathway would increase the ease of movement and of initiating movement.
2. Excitation of the indirect pathway has the net effect of inhibiting thalamic neurons (making them unable to excite motor cortex neurons).
Direct pathway selectively facilitates certain motor signals in the cerebral cortex that are needed for the present task, whereas the indirect pathway simultaneously inhibits the execution of competing motor activities. Imbalance between the direct and indirect pathways results in the motor dysfunctions.
The nigrostriatal projection
An important pathway in the processing of the direct and indirect pathways is the dopaminergic, projection from the SNc to the striatum Fig 1. 1. Direct pathway striatal neurons have D1 dopamine receptors, which depolarize the cell in response to dopamine. Thus exciting the direct pathway.
2. In contrast, indirect pathway striatal neurons have D2 dopamine receptors, which simultaneously inhibiting the indirect pathway.
The basal ganglia are also important in anatomical circuits that are involved in modulating non-motor aspects of behavior. Thus, the variation of cognitive and emotional functions in PD.
Neurotransmitters
• Glutamate are neurotransmitters having excitatory effects on their targets.
• GABA are neurotransmitters having inhibitory effects on their targets.
• Dopamine excitatory on D1 receptor & inhibitory on D2 receptor.
• The striatum has one of the highest acetylcholine concentrations of any brain structure. • role of neuroplasticity in determining dopaminergic therapy
• emphasis on physical & rehabilitative therapy with the increasing understanding of experience-dependent neuroplasticity
• acknowledging& managing non-motor problems which could be equally or at times more debilitating than the well described motor problems.
• deep brain stimulation [DBS] • LCIG Like all great discoveries evidence based benefits take time to establish.
Management of motor symptoms
Treatment is individualized to optimize quality of life, minimize side effects.
'Diagnosis does not warrant starting drugs'-is the ongoing clinical practice, and decision to start drugs is relied upon:
• symptom severity,
• whether the symptoms affect the dominant hand,
• embarrassment,
• ability to continue working and/or participate in activities such as hobbies,
• costand patient preference. With very mild symptomspatient may choose to delay therapy.
Trends may be changing
• Arguments exist whether treatment should be initiated early for dopaminergic neuronal"sparing". 3 • Recent trials suggest that people who start drug treatment soon after being diagnosed respond better than those who delay treatment and this may be related to brain plasticity.
• Furthermore dopamine-dependent corticostriatal plasticity is being investigated & drugs that target long duration response may be beneficial at this stage over those that produce short duration response paving the way for disease modification. However, these adverse effects resolve upon lowering the dose or discontinuing the medication. Echocardiography in patients receiving long-term treatment with pergolide suggests that restrictive valvular disease may be two to four times more common 7 &serosal fibrosis (pleural, pericardial and retroperitoneal). 16 So non-ergot DA(ropinirole, pramipexole, and rotigotine) are preferable to the ergot DA. 16 MAO-B inhibitors (selegiline and rasagiline) have fewer adverse effects with simple dose titration, but effects tend to be mild.
COMT inhibitors, for instance, have no intrinsic effect but increase plasmatic levels of levodopa. It has been proven efficacious for adjunct therapy with levodopa and for the treatment of motor fluctuations.Entacapone[particularly combined with L-DOPA] is widely applied in clinical practice, improving activities of daily living and reducing the "off" time in fluctuating patients. 6 Research and development of the adenosine A 2A receptor selective antagonist are ongoing.
Management of special motor symptoms • Dyskinesias and fluctuations • Freezing of gait • Camptocormia
In prolong L-DOPA therapy, random fluctuations of motor symptoms appear in majority of the responding patients. After 9 years of L-DOPA treatment, ~90% of PD patients experience dyskinesia 12 consisting of choreiform twisting &turning movements.Quality of life of the patient & caregiver deteriorates. Causes are still being looked into &the footprints of our understanding are:
• may due to fluctuations of plasma level of levodopa. Peak levels synchronizing with mobility with dyskinesia in contrast & low plasma levels with bradykinesia in combination with nonmotor fluctuations (dysautonomic, cognitive + psychiatric& pain).
Interference with absorption of levodopa by food and by competition between large neutral amino acids and levodopa for transport from plasma to the brain may be partly responsible. 8 • there may be Imbalance of dopamine receptor subtypes. Progressive depletion of endogenous dopaminergic signaling plus exogenous supply of L-DOPA induces profound changes in the neurotransmitter network of basal ganglia. An imbalance in D1 and D2 receptors, mainly expressed in the direct and indirect striatal output pathways, has been identified in dyskinetic nonhuman primates 11 . However role of D2, D3 & D5 have been suggested by other investigators.
• as the severity of PD increases, the substantial dopaminergic depletion leads to further adaptive changes in the basal ganglia pathways, including altered function of nondopaminergic basal ganglia neurotransmitters, such as glutamate, GABA, and serotonin. Excessive glutamatergic signalling within the basal ganglia is implicated in the progression of PD and in the emergence of L-DOPA induced dyskinesia [LID] . 11 • Recent studies suggested that the cerebello-thalamocortical circuit also contributes to the development of LID. 22 Trends in Managing Parkinson's Disease -A Review JM Vol. 14, No. 2
So the management is not black & white.
• Non-pharmacologic therapies improve quality of life.All PD patients should receive regular physical and/or speech therapy and should be motivated to regular exercise. 6 • The "on" freezing can be treated by reducing levodopa medication.
• The more common "off" freezing, is typically aimed at improving "on" time treatments. Catechol-o-methyl transferase inhibitors may be considered for the reduction in 'off' time in patients with advanced PD who have motor fluctuations.Intermittent subcutaneous apomorphine or LCIG may be considered for the reduction in 'off' time in patients with advanced PD. 16 • MAOB inhibitors, DA, amantadine, COMT inhibitors (e.g., combined with levodopa) provide more stable plasmatic levels and are therefore a good option. 6 NICE guidelines recommend that amantadine should be used as an anti-dyskinesia agent.NMDA glutamate receptor antagonist amantadine may significantly diminish LID. 9 Further pharmacological modulation of glutamatergic transmission is a key focus for current research.
• Drug holiday carries some risk and does not improve the efficacy of levodopa therapy or prevent the LID. 10 • Botulinum toxin injections in certain cases of freezing &camptocormia
• The implantation of electrodes for Deep Brain Stimulation for non responders.
Management of Non motor problems/syptoms [NMS]
NMS may precede PD by years [>90% of PD present with hyposmia or anosmia], be present in early disease & inescapably contribute to the severe disability of advanced disease. Focus being on the motor problems we unknowingly becomeunaware of NMS, causing a poor quality of life.
Patients not realizing the connection with PD fail to report to the doctor about sialorrhoea, sleep disturbance, urinary dysfunction, constipation, pain, hallucination, depression, anxiety, memory impairment etc.. In fact non-motor symptoms may have a more significant impact on the quality of life than the motor symptoms.
Sleep disorders: may be intrinsic to PD or may be a dose dependent side effect of dopaminergic medication. Low-dose dopamine agonists have been associated with insomnia, whereas higher doses can lead to excessive daytime sleepiness. 13 • Insomnia with consequent daytime somnolence is the most common. Education regarding healthy sleep hygiene. Clonazepam may be useful. 6 Selegiline and amantadine have stimulating properties and can induce problems with sleep initiationso should be given earlier in the day.
• Sleep attacks were first described in patients treated with pramipexole or ropinirole.
• The use of prolonged release DA should be considered, as a recent study using ropinirole prolonged release demonstrated improved subjective quality of sleep, reduced daytime sleepiness, and disappearance of sleep attacks in some PD patients 13 . Modafinil and melatonin are not recommended for the management of excessivedaytime sleepiness associated with Parkinson's disease. 16 • Restless legs syndrome (RLS). Managed by maintaining regular sleep pattern, exercise, massaging legs, heating pads or ice packs. Medications are DA, L-DOPA, benzodiazepine, gabapentin, opioids, and pregabalin.
Autonomic dysfunctions:orthostatic hypotension, gastrointestinal problems(Nausea, Constipation) & bladder and erectile dysfunction are common.
• Orthostatic hypotension: a fall of at least 20mmHg systolic and/or 10mmHg diastolic pressure within three minutes of standing. BP should be measured after 15 minutes of supine rest, and thereafter every minute for five minutes while standing, with measurement of the pulse. 14 Early onset symptomatic orthostatic hypotension is an exclusion criteria for idiopathic PD. o Reduction of dopaminergic medications, amantadine, and anticholinergics should also be considered if possible.
• Dysphagia in late stages of PD very disabling and potentially harmful, as malnutrition, dehydration, aspiration, or even asphyxia may occur. Management includes optimising dopaminergic therapy, injection of botulinum toxin. Percutaneous endoscopic gastrostomy may be a last resort. 6 • Sialorrhoeaaffects ~75% of patients with PD. 15 PD patients do not produce more saliva, problem is swallowing dysfunction. Sialorrhea is often treated with anticholinergics, but central side effects limit their usefulness.
o Glycopyrrolate(glycopyrronium bromide) is an anticholinergic drug with a quaternary ammonium structure not able to cross the blood-brain barrier in considerable amounts, is safe. 15 o Botulinum toxin is a more focused treatment.
Neuropsychiatric dysfunction: Substantia nigra & dopamine are important components involved in pleasant feeling, rewards, addiction. So a deficiency affects an individual negatively.
• Psychosis in PD refers to the combination of chronic hallucinations and delusions in the setting of otherwise clear senses. Clozapine has demonstrated efficacy in a doubleblind placebo-controlled trial; however, in clinical practice quetiapine is preferred, though not proven more effective than placebo in clinical trials. 13 Clozapine is associated with agranulocytosis and regular monitoring of blood counts weeklyfor the first 18 weeks followed fortnightly for the first year and then monthly. 16 • Dopamine dysregulation syndrome [DDS] characterized by addiction, self-medication, and escalation of antiparkinsonian medication. 13 May be accompanied by ICD.
• Impulse control disorders [ICD] such as hypomania, hypersexuality and/or gambling, and dysphoria. The prevalence of any ICD in PD patients on dopamine agonists ranges from 13.7 to 17.1%.
• Punding refers to stereotypic, complex, and repetitive behavior involving meaningless activities (i.e., examining, sorting, collecting, arranging, dismantling objects) sometimes to the point of ignoring basic needs such as eating and sleeping. Patient may be irritable when interrupted, and can lead to social avoidance and isolation.
• physicians must be aware of these neuropsychiatric side effects of dopaminergic therapy and screen for them
• family/caregiver history input can be particularly helpful as patient may deny or be embarrassed
• review of the patient's mediations is warranted, followed by a systematic reduction or cessation of dopaminergic treatment.
o For ICDs, this would meanDA. If parkinsonism worsens, it may be prudent to concomitantly increase levodopa.
o In DDS, the strategy is reversed and levodopa is weaned first, with aincrease in DA treatment.
• counseling with both the patients and their families is important.
• Antidepressants for obsessive thoughts
• Antiandrogens to help decrease hypersexuality may be considered.
• A recent study found amantadine to be effective in the treatment of pathological gambling in PD. Deep brain stimulation to the subthalamic nucleus may allow dopaminergic drug reduction and therefore improvement in these symptoms although DDS and ICDs may worsen or develop for the first time after DBS surgery. 13 • Patients should be warned about the potential for dopamine agonists to cause impulsecontrol disorders Levodopa Formulations to benefit through the day Levodopa+Carbidopa Intestinal Gel (LCIG; Duodopa): aqueous supplied in 100 ml cassettes containing 2000 mg of levodopa, enough for a full day's treatment. The cassette attaches to a portable infusion pump that pumps the gel through a transabdominal tube connected to a percutaneousendoscopic gastrostomy (PEG) tube with the tip positioned in the proximal jejunum or duodenum. The patient remains ambulatory. LCIG is effective to reduce motor fluctuations and dyskinesia in advanced PD. 18 Though expensive, invasive & inconvenient, LCIG appears to be a reasonable alternative to DBS in appropriate patients.
As levodopa can only be absorbed across a short segment of the small intestine distal to the stomach, other L-DOPA formulations that is absorbed throughout the lower GI tract are being looked into, one of them is the XP21279.
APOMORPHINE can be given in two ways: 1. subcutaneous apomorphine injections "on demand;" or 2. continuous subcutaneous injection by means of a pump.
Apomorphine is a potent DA. Increases the duration of "on" phases and is effectively applicable to patients with motor fluctuations.
Neuroplasticity is the ability of brain's neurons to compensate for injury & disease and adjust their activities in response to new situations & changes in their environment. So brain retains the capacity to overcome some of the limitations caused by disease. Neuroplasticity is possible throughout the life span. Experience-dependent neuroplasticity is the basis of current day physical & rehabilitative therapy.
Parkinson's and exercise
Progression of PD is not halted by exercise but the quality of life improves. Stronger more flexible muscles improves balance & helps to tackle motor symptoms with increased efficiency. Recent research shows that exercise seems to protect the dopamine-producing neurons helping them work better and survive for longer.
How does exercise change the brain?
Animal models of PD have shown exercise induced neuroplasticity. 19 • Fisher et al. at the University of Southern California studied the brains of mice after exercise protocols parallel to human treadmill. Observations were:
1. Exercise group a. utilized dopamine more efficiently in brain cells by modification of substantia nigra & basal ganglia. b. possessed less dopamine transporter, so dopamine signals lasted longer. c. Had an up regulation of D2 receptor.
Exercise did not have any effect on amount of dopamine
nor the number of neurons.
They also studied the D2 receptor in a subset of the human subjects who were within one year of diagnosis and not on any medications, using PET imaging & found increased the number of D2 receptors.
• At the University of Pittsburgh researchers showed, exercise induces and increases neurotrophic factors, like GDNF (glial-derived)in animal models, which may be neuroprotective.
• Forced exercise[FE] is defined as active aerobic exercise where exercise rate is augmented mechanically to help the participant achieve and maintain a rate that is greater than their preferred voluntary rate of exercise. It is postulated that FE increases afferent signals from golgi tendon organs & muscle spindles hence triggering the release of neurotrophic factors & possibly dopamine.
• Exercise interventions in PD incorporate goal-based motor skill training to engage cognitive circuitry important in motor learning. Through instruction, feedback & encouragement individuals become more cognitively engaged in learning movements that were automatic & unconscious in their earlier life like swallowing, speaking, walking etc.. Goal based aerobic exercise has the potential to improve both cognitive & automatic components of motor control in mild to moderate PD through experience-dependent neuroplasticity. 20 • Some of the different types of exercise, include tai chi, tango dancing, Feldenkrais method, gym training and hydrotherapy, Lee Silverman Voice Treatment.
Deep Brain Stimulation[DBS]
has become the surgical procedure of choice for PD for the following reasons:
• It does not involve destruction of brain tissue
• It is reversible
• It can be adjusted as the disease progresses or adverse events occur
• Bilateral procedures can be performed without a significant increase in adverse events.
A better understanding of basal ganglia physiology and circuitry and improvements in surgical techniques, neuroimaging, and electrophysiology have allowed surgical procedures to be performed more accurately with lower morbidity.
Surgery for movement disorders previously involved predominantly destructive lesioning of abnormally hyperactive deep brain nuclei; however, the observation that high-frequency electrostimulation in the ventral lateral nucleus (VL) of the thalamus eliminates tremors in patients undergoing thalamotomy led to investigation of long-term DBS as a reversible alternative. Focus of movement disorder surgery are 3 key gray-matter structures: the thalamus, the globuspallidus, and the subthalamic nucleus (STN). Currently, the STN is the most commonly targeted site for PD.
Targets for pharmacotherapy & beyond
With loss of nigrostriatal neurones there is 1. dampening of direct pathway &
release of indirect pathway
Net effect is an overactive GPi, strongly inhibiting the thalamus and causing a reduction in cortical activity, causing hypokinesia [ Fig.-2] . End of dose deterioration is signaled when the effect of L DOPA wanes off about 4 hours after the last dose. First approach is then to fine tune L DOPA therapy to provide more sustained dopamine levels:
Physicians resorts to
Then attempting to lower L-DOPA dose.
2. Frequent L-DOPA dosing: smaller doses are administered more frequently. The time to wearing-off determines the interdose interval. In extreme cases using liquid levodopa, the dose can be titrated finely and administered every hour.
3. Increasing L-DOPA dose
Switching from immediate-releaseto
• sustained or extended release(CR) levodopa/carbidopa or 
